Geode Capital Management LLC Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)

Geode Capital Management LLC acquired a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 308,930 shares of the company’s stock, valued at approximately $4,774,000. Geode Capital Management LLC owned 1.27% of Artiva Biotherapeutics at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the company. State Street Corp bought a new position in Artiva Biotherapeutics during the 3rd quarter worth $1,337,000. BNP Paribas Financial Markets bought a new position in shares of Artiva Biotherapeutics during the third quarter worth approximately $42,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Artiva Biotherapeutics during the 3rd quarter valued at $623,000. Wellington Management Group LLP acquired a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth $2,912,000. Finally, RA Capital Management L.P. bought a new position in shares of Artiva Biotherapeutics in the third quarter worth $152,234,000.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ARTV. HC Wainwright initiated coverage on shares of Artiva Biotherapeutics in a research report on Monday, December 30th. They set a “buy” rating and a $20.00 price target on the stock. Needham & Company LLC restated a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Artiva Biotherapeutics currently has an average rating of “Buy” and an average price target of $21.00.

Artiva Biotherapeutics Price Performance

NASDAQ:ARTV opened at $10.67 on Monday. The company has a fifty day moving average of $11.37. Artiva Biotherapeutics, Inc. has a twelve month low of $9.68 and a twelve month high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.24). Analysts forecast that Artiva Biotherapeutics, Inc. will post -4.68 EPS for the current fiscal year.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.